- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07943637
Nutritional Status Evaluation in Underweight Indonesian Children Receiving 0.89 kcal/mL Milk Powder - Site Manado (GROW)
Evaluation of the Nutritional Status of Underweight Indonesian Children Receiving 0.89 kcal/mL Milk Powder: An Open-Label, Single-Arm, Prospective Study (GROW Study)
The goal of this clinical trial is to learn whether daily use of Investigational Product (IP), an energy-dense milk powder, improves growth in Indonesian children aged 24 to 48 months who are underweight. The main question it aims to answer is whether Investigational Product (IP) improves children's weight relative to their age after 6 months of use.
Researchers will also assess changes in height, weight relative to height, body mass index, head size, growth rate, digestive comfort, and safety.
Participants will:
- Complete a 7-day feeding trial to check whether they can tolerate and accept the study product.
- Drink two servings of Investigational Product (IP) each day for 6 months.
- Visit the study site regularly for growth measurements and other study assessments.
- Record daily product intake and digestive symptoms, and report any health problems during the study.
The study will enroll at least 74 children combined from 2 sites (Manado, 37 children; Makassar, 37 children). All participants will receive Investigational Product (IP). There is no placebo or comparison group.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
This study evaluates the effect of daily supplementation with Investigational Product (IP), an energy-dense milk powder providing 0.89 kcal/mL, on the nutritional status and growth of Indonesian children aged 24 to 48 months who are underweight.
The study uses an open-label, single-arm, prospective interventional design. All enrolled participants receive the same study product, and there is no randomization, blinding, placebo, or non-intervention control group. Changes during the intervention are evaluated by comparing each participant's measurements with their baseline values. The study design was selected because the study population consists of children with moderate underweight, and withholding nutritional support through a placebo or non-intervention group was considered inappropriate in the study protocol.
Before enrollment, potentially eligible children complete a 7-day feeding trial. During this period, caregivers prepare and provide the study product according to standardized instructions and record daily intake, leftovers, and gastrointestinal symptoms. The feeding trial is used to assess initial product acceptance and gastrointestinal tolerance. Children who successfully complete the feeding trial and remain eligible proceed to the baseline assessment and the 6-month intervention period.
During the intervention period, participants consume two servings of Investigational Product (IP) each day for approximately 6 months. The study product is dispensed regularly, and caregivers record daily product consumption and gastrointestinal symptoms in study diaries. Study staff review product use and returned product packaging to assess adherence. Safety monitoring for adverse events and serious adverse events continues throughout the study.
Growth and nutritional status are assessed during scheduled study visits using anthropometric measurements. Additional assessments are used to characterize gastrointestinal tolerance, body composition and body measurements, child behavioral and emotional functioning, dietary patterns, product acceptability, caregiver satisfaction, and safety.
The study plans to enroll at least 74 children, with at least 37 participants recruited at each of the two study sites in Manado and Makassar. An interim analysis is planned around Month 3 to review data completeness, protocol adherence, participant safety, and overall study progress. The interim analysis is descriptive and exploratory and is not intended for formal efficacy hypothesis testing.
The study is intended to provide information on the potential effect of 6 months of milk product supplementation on growth and nutritional status, while also describing gastrointestinal tolerance, safety, product acceptability, and other related nutritional and developmental measures in this population.
Studietype
Registrering (Antatt)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
- Navn: Bobby Pambudi, Sp.A,Subsp. NPM(K)
- Telefonnummer: +62 853-4020-7704
- E-post: bobbypambudimd@gmail.com
Studiesteder
-
-
North Sulawesi
-
Manado, North Sulawesi, Indonesia, 95239
- Rekruttering
- Puskesmas Tuminting
-
Ta kontakt med:
- Bobby Pambudi, Sp.A,Subsp. NPM(K)
- Telefonnummer: +62 853-4020-7704
- E-post: bobbypambudimd@gmail.com
-
Hovedetterforsker:
- Bobby Pambudi, Sp.A,Subsp. NPM(K)
-
Underetterforsker:
- Lydia Wangke, Sp.A (K)
-
Underetterforsker:
- Ronald Rompies, SpA, Subsp. NPM (K)
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Children aged 24 to 48 months at the time of enrollment.
- Classified as underweight according to the World Health Organization Growth Standards 2006, with a Weight-for-Age Z-score below -2.
- Willing to participate and consume the study product, a milk powder providing 0.89 kcal/mL, during the 7-day feeding trial and 6-month intervention period.
- Parent or legal guardian has provided signed informed consent before participation
- No plan to relocate or move residence within the next 8 months during the study period
- Able and willing to comply with study procedures, including scheduled visits, dietary recalls, and product consumption recording
- Completed the 7-day feeding trial and demonstrated tolerance of the study product without aversion, intolerance, or allergic reaction, as confirmed by the study physician
- Parent or primary caregiver has adequate literacy to understand study instructions, with a minimum education level of completed senior high school.
Exclusion Criteria:
- History of preterm birth, defined as gestational age below 37 weeks
- Birth weight below 2,500 g or above 4,000 g
- Weight-for-Height Z-score below -2 standard deviations, indicating moderate acute malnutrition
- Height-for-Age Z-score below -2, indicating stunting
- Presence of historic of chronic or infectious diseases, including tuberculosis, congenital heart disease, or other acute or chronic illness that may affect nutritional intake or growth
- Diagnosed cow's milk protein allergy or lactose intolerance by a healthcare professional
- Currently participating in another clinical or nutrition intervention study
- Presence of signs suggestive of anemia, identified through non-invasive physical examination by a pediatric clinician
- Inability to tolerate or complete the 7-day feeding trial, including moderate to severe gastrotinestinal symptoms related to the study product or inability to complete 7 full days of product consumption
- Any condition that, in the investigator's judgement, makes the child unsuitable for the study
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: GROPLUS Milk Powder
Participants will receive GROPLUS milk powder with an energy density of 0.89 kcal/mL for 6 months. Participants will consume two servings of the study product each day according to standardized preparation and administration instructions. Study staff will monitor product use, gastrointestinal tolerance, adherence, and safety throughout the intervention period. |
GROPLUS is an energy-dense milk powder providing 0.89 kcal/mL when prepared according to the study instructions. Participants will consume two servings per day for approximately 6 months. The product will be prepared and administered according to standardized study instructions, with product use and compliance monitored throughout the intervention period. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in Weight-for-Age Z-score from Baseline to Month 6
Tidsramme: From baseline (Month 0) to Month 6
|
Change in Weight-for-Age Z-score (WAZ), calculated using the 2006 World Health Organization Child Growth Standards. Weight and age measurements collected at baseline and Month 6 will be used to determine WAZ. The change will be calculated as the difference between the Month 6 and baseline WAZ values and evaluated against a predefined minimal clinically important difference of 0.20 Z-score. |
From baseline (Month 0) to Month 6
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Height Gain Velocity from Baseline to Month 6
Tidsramme: From baseline (Month 0) to Month 6
|
Rate of height gain expressed in millimeters per month (mm/month), calculated from serial height measurements collected during the study. Height velocity will be assessed between baseline and Month 6. |
From baseline (Month 0) to Month 6
|
|
Incidence and Frequency of Adverse Events and Common Infectious Illnesses
Tidsramme: From baseline (Month 0) through Month 6
|
The incidence and frequency of adverse events during the intervention period, including common infectious illnesses such as upper respiratory tract infection, diarrhea, and fever. Adverse events will be monitored and documented throughout the intervention period. |
From baseline (Month 0) through Month 6
|
|
Change in Height-for-Age Z-score from Baseline to Month 6
Tidsramme: From baseline (Month 0) to Month 6
|
Change in Height-for-Age Z-score (HAZ), calculated using the 2006 World Health Organization Child Growth Standards. Height measurements collected at baseline and Month 6 will be used to assess change in linear growth. |
From baseline (Month 0) to Month 6
|
|
Change in Weight-for-Height Z-score from Baseline to Month 6
Tidsramme: From baseline (Month 0) to Month 6
|
Change in Weight-for-Height Z-score (WHZ), calculated using the 2006 World Health Organization Child Growth Standards. Weight and height measurements collected at baseline and Month 6 will be used to assess proportional growth and weight relative to height. |
From baseline (Month 0) to Month 6
|
|
Change in Body Mass Index-for-Age Z-score from Baseline to Month 6
Tidsramme: From baseline (Month 0) to Month 6
|
Change in Body Mass Index-for-Age Z-score (BAZ), calculated from body mass index measurements standardized using World Health Organization reference values. The change will be assessed between baseline and Month 6. |
From baseline (Month 0) to Month 6
|
|
Change in Head Circumference-for-Age Z-score from Baseline to Month 6
Tidsramme: From baseline (Month 0) to Month 6
|
Change in Head Circumference-for-Age Z-score (HCZ), calculated using the 2006 World Health Organization Child Growth Standards. Head circumference measurements collected at baseline and Month 6 will be used to assess change. |
From baseline (Month 0) to Month 6
|
|
Weight Gain Velocity from Baseline to Month 6
Tidsramme: From baseline (Month 0) to Month 6
|
Rate of weight gain expressed in grams per month (g/month), calculated from serial body weight measurements collected during the study. Weight velocity will be assessed between baseline and Month 6 |
From baseline (Month 0) to Month 6
|
|
Change in Gastrointestinal Tolerance from Baseline to Month 6
Tidsramme: From baseline (Month 0) to Month 6
|
Change in gastrointestinal tolerance assessed using the Toddler Gut Comfort Questionnaire (TGCQ). The assessment includes total and domain scores reflecting gastrointestinal comfort. Scores will be compared between baseline and Month 6. |
From baseline (Month 0) to Month 6
|
|
Change in Mid-Upper Arm Circumference from Baseline to Month 6
Tidsramme: From baseline (Month 0) to Month 6
|
Change in mid-upper arm circumference measured in centimeters (cm), based on measurements collected at baseline and Month 6. |
From baseline (Month 0) to Month 6
|
|
Change in Waist Circumference from Baseline to Month 6
Tidsramme: From baseline (Month 0) to Month 6
|
Change in waist circumference measured in centimeters (cm), based on measurements collected at baseline and Month 6. |
From baseline (Month 0) to Month 6
|
|
Change in Hip Circumference from Baseline to Month 6
Tidsramme: From baseline (Month 0) to Month 6
|
Change in hip circumference measured in centimeters (cm), based on measurements collected at baseline and Month 6 |
From baseline (Month 0) to Month 6
|
|
Change in Head Circumference from Baseline to Month 6
Tidsramme: From baseline (Month 0) to Month 6
|
Change in head circumference measured in centimeters (cm), based on measurements collected at baseline and Month 6. |
From baseline (Month 0) to Month 6
|
|
Calf Circumference from Baseline to Month 6
Tidsramme: From baseline (Month 0) to Month 6
|
Change in calf circumference measured in centimeters (cm), based on measurements collected at baseline and Month 6. |
From baseline (Month 0) to Month 6
|
|
Change in Triceps Skinfold Thickness from Baseline to Month 6
Tidsramme: At baseline (Month 0), Month 3, and Month 6
|
Change in triceps skinfold thickness measured in millimeters (mm), based on measurements collected at baseline and Month 6. |
At baseline (Month 0), Month 3, and Month 6
|
|
Change in Biceps Skinfold Thickness from Baseline to Month 6
Tidsramme: From baseline (Month 0) to Month 6
|
Change in biceps skinfold thickness measured in millimeters (mm), based on measurements collected at baseline and Month 6. |
From baseline (Month 0) to Month 6
|
|
Subscapular Skinfold Thickness from Baseline to Month 6
Tidsramme: From baseline (Month 0) to Month 6
|
Change in subscapular skinfold thickness measured in millimeters (mm), based on measurements collected at baseline and Month 6. |
From baseline (Month 0) to Month 6
|
|
Change in Abdominal Skinfold Thickness from Baseline to Month 6
Tidsramme: From baseline (Month 0) to Month 6
|
Change in abdominal skinfold thickness measured in millimeters (mm), based on measurements collected at baseline and Month 6. |
From baseline (Month 0) to Month 6
|
|
Change in Knee Height from Baseline to Month 6
Tidsramme: At baseline (Month 0), Month 3, and Month 6
|
Change in knee height, measured in centimeters (cm), assessed using Anthropometer Caliper. Measurements will be collected at baseline, Month 3, and Month 6 to assess changes in knee height over the study period. |
At baseline (Month 0), Month 3, and Month 6
|
|
Change in Arm Span from Baseline to Month 6
Tidsramme: At baseline (Month 0), Month 3, and Month 6
|
Change in arm span measured at baseline, Month 3, and Month 6. Measurements will be compared across the specified assessment time points. |
At baseline (Month 0), Month 3, and Month 6
|
Andre resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in Child Behavioral and Emotional Functioning
Tidsramme: At baseline (Month 0), Month 3, and Month 6
|
Change in child behavioral and emotional functioning assessed using the Child Behavior Checklist (CBCL). Assessments will be conducted at baseline, Month 3, and Month 6, including internalizing, externalizing, and total problem scores. |
At baseline (Month 0), Month 3, and Month 6
|
|
Baseline Dietary Patterns and Macronutrient Intake
Tidsramme: At baseline (Month 0)
|
Baseline habitual dietary patterns and macronutrient intake assessed using a validated Food Frequency Questionnaire (FFQ) before the 6-month supplementation period. |
At baseline (Month 0)
|
|
Caregiver-Reported Child Liking of Product Appearance
Tidsramme: Every 2 weeks from baseline through Month 6
|
Child's liking of the study product's appearance, as reported by the parent or caregiver using the study-specific Child Product Liking Questionnaire with a pictorial response scale. Responses are categorized as dislike (0), neutral (1), or like (2), with a possible score range of 0 to 2. Higher scores indicate greater liking. |
Every 2 weeks from baseline through Month 6
|
|
Caregiver-Reported Child Liking of Product Taste
Tidsramme: Every 2 weeks from baseline through Month 6
|
Child's liking of the study product's taste, as reported by the parent or caregiver using the study-specific Child Product Liking Questionnaire with a pictorial response scale. Responses are categorized as dislike (0), neutral (1), or like (2), with a possible score range of 0 to 2. Higher scores indicate greater liking. |
Every 2 weeks from baseline through Month 6
|
|
Caregiver-Reported Child Liking of Product Texture
Tidsramme: Every 2 weeks from baseline through Month 6
|
Child's liking of the study product's texture, as reported by the parent or caregiver using the study-specific Child Product Liking Questionnaire with a pictorial response scale. Responses are categorized as dislike (0), neutral (1), or like (2), with a possible score range of 0 to 2. Higher scores indicate greater liking |
Every 2 weeks from baseline through Month 6
|
|
Parent or Caregiver Satisfaction with Product Use and Feeding Experience
Tidsramme: Every 2 weeks from baseline through Month 6
|
Parent or caregiver satisfaction with the nutritional quality of the study product, assessed using the study-specific Parent/Caregiver Satisfaction Questionnaire. Responses are categorized as yes, neutral, no, or unwilling to respond. Results will be reported as the number and percentage of participants in each response category. |
Every 2 weeks from baseline through Month 6
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- CR.202/EQL/2025_MAN
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
There is no plan to share individual participant data (IPD) with other researchers. The study data will be maintained by the Sponsor and study team and will be used for the purposes described in the study protocol. Participant confidentiality and data privacy will be maintained.
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .